Compugen Ltd. (NASDAQ:CGEN) Short Interest Update

Compugen Ltd. (NASDAQ:CGEN) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 2,090,000 shares, an increase of 11.8% from the March 15th total of 1,870,000 shares. Based on an average trading volume of 651,500 shares, the short-interest ratio is currently 3.2 days.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Compugen during the first quarter valued at approximately $37,000. Janney Montgomery Scott LLC boosted its holdings in shares of Compugen by 58.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 21,700 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 8,000 shares during the period. Advisor Group Holdings Inc. boosted its holdings in shares of Compugen by 29.3% in the first quarter. Advisor Group Holdings Inc. now owns 27,241 shares of the biotechnology company’s stock valued at $87,000 after buying an additional 6,174 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of Compugen by 23.4% in the first quarter. Envestnet Asset Management Inc. now owns 33,260 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 6,299 shares during the period. Finally, Mariner LLC boosted its holdings in shares of Compugen by 207.3% in the fourth quarter. Mariner LLC now owns 36,831 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 24,844 shares during the period. Institutional investors and hedge funds own 12.22% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Stifel Nicolaus lifted their price target on shares of Compugen from $3.00 to $4.00 and gave the company a “buy” rating in a report on Tuesday, December 19th. StockNews.com upgraded shares of Compugen from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th.

Compugen Trading Up 3.6 %

Shares of NASDAQ:CGEN traded up $0.07 during trading on Tuesday, hitting $2.03. 451,043 shares of the company’s stock were exchanged, compared to its average volume of 650,892. The firm has a market cap of $175.84 million, a P/E ratio of -9.23 and a beta of 2.64. The firm has a 50-day moving average price of $2.47 and a two-hundred day moving average price of $1.66. Compugen has a 1-year low of $0.53 and a 1-year high of $3.03.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Tuesday, March 5th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. The firm had revenue of $33.46 million for the quarter, compared to analyst estimates of $60.00 million. As a group, research analysts predict that Compugen will post 0.02 EPS for the current year.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.